Patents by Inventor Sven Warnaar

Sven Warnaar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hybridoma cell line G250 and its use for producing monoclonal antibodies
    Patent number: 9605075
    Abstract: This invention relates to a hybridoma cell line which is capable of producing the monoclonal antibody G250. Furthermore, the invention describes the method of employing such cell line for the production and manufacture of monoclonal antibody G250 as well as derivatives thereof such as chimeric and humanized G250 antibodies.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: March 28, 2017
    Assignee: WILEX AG
    Inventors: Egbert Oosterwijk, Sven Warnaar, Stefan Ullrich
  • Adjuvant theraphy of G250-expressing tumors
    Patent number: 7691375
    Abstract: The invention relates to a method for the treatment of G250-antigen-expressing tumors, in particular renal clear cell carcinoma comprising the administration of G250-antigen-specific antibodies to high-risk patients diagnosed with non-metastasizing disease.
    Type: Grant
    Filed: June 29, 2005
    Date of Patent: April 6, 2010
    Assignee: Wilex AG
    Inventors: Olaf Wilhelm, Sven Warnaar
  • Hybridoma Cell Line G250 and its use for Producing Monoclonal Antibodies
    Publication number: 20090274620
    Abstract: This invention relates to a hybridoma cell line which is capable of producing the monoclonal antibody G250.
    Type: Application
    Filed: December 23, 2008
    Publication date: November 5, 2009
    Applicant: Wilex AG
    Inventors: Egbert OOSTERWIJK, Sven WARNAAR, Stefan ULLRICH
  • Hybridoma cell line G250 and its use for producing monoclonal antibodies
    Publication number: 20080138275
    Abstract: This invention relates to a hybridoma cell line which is capable of producing the monoclonal antibody G250. Furthermore, the invention describes the method of employing such cell line for the production and manufacture of monoclonal antibody G250 as well as derivatives thereof such as chimeric and humanized G250 antibodies.
    Type: Application
    Filed: January 19, 2007
    Publication date: June 12, 2008
    Applicant: WILEX AG
    Inventors: Egbert Oosterwijk, Sven Warnaar
  • Adjuvant Theraphy of G250-Expressing Tumors
    Publication number: 20070207157
    Abstract: The invention relates to a method for the treatment of G250-antigen-expressing tumors, in particular renal clear cell carcinoma comprising the administration of G250-antigen-specific antibodies to high-risk patients diagnosed with non-metastasising disease.
    Type: Application
    Filed: June 29, 2005
    Publication date: September 6, 2007
    Applicant: Wilex AG
    Inventors: Olaf Wilhelm, Sven Warnaar
  • Co-administration of cg250 and il-2 or ifn-alpha for threating cancer such as renal cell carcinomas
    Publication number: 20050261178
    Abstract: A method for enhancing the therapeutic effect of cytokine treatment is disclosed. More specifically the present invention relates to a method for administering to a tumor patient a therapeutic dose of cytokine in combination with antibodies directed against the tumor associated antigen carbonic anhydrase IX (CAIX/G250/MN). The improved treatment method is characterized in a significantly reduced cytokine-related toxicity combined with potentiated effectiveness of anti-G250 antibody alone, resulting in a positive therapeutic response with respect to that observed with single anti-tumor agents alone.
    Type: Application
    Filed: June 23, 2003
    Publication date: November 24, 2005
    Applicant: WILEX AG
    Inventors: Sven Warnaar, Stefan Ullrich
  • Hybridoma cell line g250 and its use for producing monoclonal antibodies
    Publication number: 20040077081
    Abstract: The invention relates to a hybridoma cell line which is capable of producing the monoclonal antibody G250. Furthermore, the invention describes the method of employing such cell line for the production and manufacture of monoclonal antibody G250 as well as derivatives thereof such as chimeric and humanized G250 antibodies.
    Type: Application
    Filed: August 5, 2003
    Publication date: April 22, 2004
    Inventors: Egbert Oosterwijk, Sven Warnaar, Stefan Ullrich